

BRETT GUTHRIE, KENTUCKY
CHAIRMAN

FRANK PALLONE, JR., NEW JERSEY
RANKING MEMBER

ONE HUNDRED NINETEENTH CONGRESS
Congress of the United States
House of Representatives
COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115
Majority (202) 225-3641
Minority (202) 225-2927

October 8, 2025

Todd Brinton, M.D., F.A.C.C.
Edwards Lifesciences LLC
601 13th St. NW, Suite 350S
Washington, DC 20005

Dear Dr. Brinton:


Thank you for appearing before the Subcommittee on Health on Thursday, September 18, 2025, to testify at the hearing entitled "Examining Policies to Enhance Seniors' Access to Breakthrough Medical Technologies."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on Thursday, October 23, 2025. Your responses should be mailed to Annabelle Huffman, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, DC 20515 and e-mailed in Word format to Annabelle.Huffman@mail.house.gov.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



H. Morgan Griffith
Chairman
Subcommittee on Health

cc: Diana DeGette, Ranking Member, Subcommittee on Health

Attachment

Attachment — Additional Questions for the Record

The Honorable Mariannette Miller-Meeks (R-IA)

1. Even when a breakthrough medical technology is FDA-cleared or approved, patients in rural communities often wait years for coverage and access — especially when those technologies are not traditional drugs or devices, but software-driven innovations like autonomous artificial intelligence systems that bring specialist-level diagnostic care directly into primary care and other frontline settings.
 - a. What do you believe are the most effective steps Congress and CMS can take to ensure that these kinds of diagnostic and preventive innovations reach rural and aging populations more quickly — particularly when they improve chronic disease management, close care gaps, support earlier detection of disease, and reduce pressure on limited specialist capacity?